Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 15/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4074289 | 1.00 | CCR2 (0.61) | CCR2RAB9ANPC1ALDH1A1 | |
| SCHEMBL4074292 | 1.00 | CCR2 (0.61) | CCR2RAB9ANPC1ALDH1A1 | |
| SCHEMBL8317734 | 0.95 | CCR2 (0.69) | CCR2RAB9ANPC1ALDH1A1 | |
| SCHEMBL3954242 | 0.95 | CCR2 (0.69) | CCR2RAB9ANPC1ALDH1A1 | |
| SCHEMBL12332205 | 0.89 | CCR2 (0.51) | CCR2RAB9ANPC1 | |
| SCHEMBL12285520 | 0.89 | CCR2 (0.51) | CCR2RAB9ANPC1 | |
| SCHEMBL3733678 | 0.89 | CCR2 (0.51) | CCR2RAB9ANPC1 | |
| SCHEMBL12831212 | 0.86 | CCR2 (0.58) | CCR2RAB9ANPC1ALDH1A1 | |
| SCHEMBL12831373 | 0.86 | CCR2 (0.58) | CCR2RAB9ANPC1ALDH1A1 | |
| SCHEMBL20581684 | 0.83 | CCR2 (0.60) | CCR2RAB9ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013036684-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | SATORI PHARMACEUTICALS, INC (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2011109657-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | SATORI PHARMACEUTICALS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| US-7531657-B2 | Method for preparing sulphostin and analogue thereof or preparation intermediate thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-05-12 | — | — | US | disclosed |
| US-20050020834-A1 | Method for preparation of sulphostin and its analogue or intermediates thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1457494-A1 | PROCESSES FOR PREPARATION OF SULPHOSTIN AND ITS ANALOGUES OR INTERMEDIATES THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2004-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020834-A1 | Method for preparation of sulphostin and its analogue or intermediates thereof | SOST, PTMS, FGF23 | CCR2 1659/4885RAB9A 3013/4885NPC1 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.